As the world yearns to return to normal life after more than a year of living the pandemic, countries are competing to administer vaccines that should slow down – and hopefully stop coronavirus.
Doing so successfully will depend on a number of factors, from manufacturing and transporting billions of doses, to ensuring rich nations do not monopolize the global supply of vaccines and, fundamentally, getting doses into people’s arms.
The following graphs and maps will be updated to show the latest data on the largest vaccination release in history, in the United States and around the world.
There are notable differences from state to state in how quickly vaccines are given to people.
The first two vaccines approved per emergency use in the United States, developed by companies Pfizer / BioNTech i Modern, are designed to be administered in two separate doses several weeks. He Johnson & Johnson the vaccine authorized for use in late February requires only one dose. Therefore, vaccinating everyone in the United States would mean ending up giving between 100 and 200 doses for every 100 people in each state and territory, or a total of between 330 million and 660 million doses for the entire nation. It is a huge logistical challenge.
Deployment of vaccines in the United States began more slowly than expected. The Trump administration set itself the goal of giving 20 million vaccines by the end of 2020. This goal was not achieved until the end of January. In early March, President Joe Biden said the U.S. would have enough vaccines for all adults in late May – two months earlier than planned by his administration. However, there is concern that the vaccine will become poorer people i communities of color behind.
Search or browse this table to find the performance of your state or territory in these key vaccine deployment measures.
Chronology of vaccine release
This graph shows the number of vaccines administered per 100 people for each state since early 2021. The top three states and U.S. national numbers stand out. Type the name of any other US state or territory in the search bar and select to add to the chart.
This graph shows the daily number of vaccine doses administered nationwide since the beginning of 2021. Due to data uploads due to reporting lags, the line showing the rotating average dose of vaccines Given 7 days gives a clearer idea of whether the launch is accelerating or slowing down.
Launch of vaccines by country
This map shows more countries showing the doses of vaccine administered per 100 people, as these figures are more widely reported.
The United States is ahead of most other countries in vaccine launching. But among the major nations has been Israel first leader.
Search or browse this table to see how each country is doing. It reveals that some nations have adopted different strategies: the UK, for example, decided to give as many people as possible an initial dose, delaying its second take.
Chronology of vaccine release
This graph shows the number of vaccines administered per 100 people for each country since early 2021. Enter the name of any nation in the search bar and select to compare its timeline with the United States and the other three major countries. presenting vaccines worldwide. Only countries that have started their vaccination campaigns will appear.
This graph shows the daily number of vaccine doses given to people around the world. Due to the rises due to lags in reporting, the line showing the given two-day average dose gives a clearer idea of whether the release is accelerating or decreasing.
Status of leading vaccines
This table documents the status of major COVID-19 vaccines, which show authorizations for use in the United States and other selected markets, in addition to the information prices of purchase agreements. compiled by UNICEF, when available.
Pfizer / BioNTech and Moderna vaccines, with clinical trial results indicating yes more than 90% effective in the prevention of diseases, they are based on a new technology which provides an RNA sequence that causes our own cells to produce viral proteins, triggering an immune response.
The disadvantage is that these vaccines are more expensive than those produced by combining coronavirus genetic material in an inactivated version of another virus, such as those produced by the Anglo-Swedish company AstraZeneca, based on Oxford University research, Johnson & Johnson, and from Russia Gamaleya Research Institute.
Other leading vaccines rely on inactivated versions of coronavirus, a long-standing approach to making vaccines or protein subunits of the virus.
Jeremy Singer-Vine contributed the news of this story.